IP Library Granted Patent US 8,084,047
Granted Patent B2
US 8,084,047 · App. 12/508,367 · Granted Dec 27, 2011

Compositions and methods for treatment of eye disorders

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,084,047
App. No.
12/508,367
Granted
Dec 27, 2011
Kind
B2
Abstract

The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.

Claims (6)

1. A compound with the following formula:

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising an effective amount of a compound of claim 1 and a pharmaceutically acceptable vehicle.

3. The pharmaceutical composition of claim 2 wherein the pharmaceutically acceptable vehicle is suitable for ocular administration.

4. The pharmaceutical composition of claim 3 further comprising a preservative.

5. The pharmaceutical composition of claim 2 wherein the composition form is liquid drops, liquid wash, gel, ointment, liposomes, solution, cream, powder, foam, crystals, spray, aerosol, or liquid suspension.

Assignments (15)
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Dec 23, 2025
From: BAUSCH + LOMB IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT
Reel/Frame 074050/0573 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Dec 23, 2025
From: BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 074050/0682 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Dec 23, 2025
From: BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 074050/0709 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 6, 2023
From: NOVARTIS PHARMACEUTICALS CORPORATION
To: BAUSCH + LOMB IRELAND LIMITED
Reel/Frame 065789/0853 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2020
From: NOVARTIS AG
To: NOVARTIS PHARMACEUTICALS CORPORATION
Reel/Frame 054134/0708 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2019
From: SARCODE BIOSCIENCE INC.
To: NOVARTIS AG
Reel/Frame 050900/0268 →
RELEASE OF SECURITY INTEREST Recorded Apr 25, 2013
From: SILICON VALLEY BANK
To: SARCODE BIOSCIENCE INC.
Reel/Frame 030295/0028 →
MERGER Recorded Feb 13, 2013
From: SARCODE, A CALIFORNIA CORPORATION
To: SARCODE CORPORATION, A CORPORATION OF STATE OF DELAWARE
Reel/Frame 029804/0051 →
SECURITY AGREEMENT Recorded Feb 8, 2013
From: SARCODE BIOSCIENCE INC.
To: SILICON VALLEY BANK
Reel/Frame 029778/0888 →
CHANGE OF NAME Recorded Sep 8, 2011
From: SARCODE CORPORATION
To: SARCODE BIOSCIENCE INC.
Reel/Frame 026876/0312 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 29, 2011
From: ZHONG, MIN
To: SUNESIS PHARMACEUTICALS, INC.
Reel/Frame 026043/0509 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 29, 2011
From: SUNESIS PHARMACEUTICALS, INC.
To: SARCODE CORPORATION
Reel/Frame 026043/0842 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2010
From: SUNESIS PHARMACEUTICALS, INC.
To: SARCODE CORPORATION
Reel/Frame 025184/0125 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2010
From: SHEN, WANG; OSLOB, JOHAN D.; BARR, KENNETH
To: SUNESIS PHARMACEUTICALS, INC.
Reel/Frame 025145/0668 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2010
From: GADEK, THOMAS; BURNIER, JOHN
To: SARCODE CORPORATION
Reel/Frame 025147/0333 →